BCAX
Bicara Therapeutics Inc. Common Stock · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -4.7% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 71 | +6 | 22.19M | $658.02M | +11 | −5 |
| Q1 2026 | 68 | +4 | 22.46M | $446.36M | +8 | −5 |
| Q4 2025 | 65 | 0 | 22.60M | $380.21M | +3 | −2 |
| Q3 2025 | 13 | -1 | 12.02M | $189.85M | — | −2 |
| Q2 2025 | 12 | 0 | 11.43M | $106.16M | +3 | −3 |
| Q1 2025 | 9 | +1 | 5.34M | $69.55M | +2 | −1 |
| Q4 2024 | 8 | -3 | 5.77M | $100.60M | +1 | −4 |
| Q3 2024 | 10 | +10 | 4.16M | $105.86M | +10 | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 2.54M | — | $23.58M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | T. Rowe Price ✦ | 2.15M | +19.6% | $19.98M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | BlackRock ✦ (passive) | 2.11M | — | $19.61M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 4 | The Vanguard Group ✦ (passive) | 2.01M | — | $18.63M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 5 | Millennium Management ✦ | 741.02K | +2789.2% | $6.88M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 672.49K | +36.8% | $6.25M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passive) | 541.07K | +46.2% | $5.03M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 221.52K | New | $2.06M | 0.0% | New | 1 | SEC ↗ |
| 9 | Point72 Asset Management ✦ | 216.84K | New | $2.01M | 0.0% | New | 1 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 134.46K | +952.9% | $1.25M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Marshall Wace ✦ | 51.81K | New | $481,306 | 0.0% | New | 1 | SEC ↗ |
| 12 | Norges Bank ✦ (passive) | 42.89K | 0.0% | $398,439 | 0.0% | Held | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $2.06M | 0.0% |
| Point72 Asset Management | $2.01M | 0.0% |
| Marshall Wace | $481,306 | 0.0% |
Exited
| Wellington Management | $18.17M | was 0.0% |
| Adage Capital Partners | $15.41M | was 0.0% |
| AQR Capital Management | $248,013 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 146 holders, 71.07M shares, $1.23B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 14.06K sh · $320,053
Officer, Director · 3.44K sh · $80,663
Officer, Director · 10.00K sh · $279,750
Officer · 12.50K sh · $349,591
Officer, Director · 18.75K sh · $524,533
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology